Preclinical Gene Therapy Programme for Hurler Syndrome
Researchers are developing a new type of treatment for Hurler syndrome (severe MPS I, MPS I-H) using gene therapy. Instead of giving enzyme by regular infusions or relying only on a bone marrow transplant, gene therapy aims to give the body a working copy of the IDUA gene so that cells can make alpha-L-iduronidase themselves, every day, for many years.
This page summarises, in plain language, the design, aims and key findings of a preclinical gene therapy programme for Hurler syndrome carried out in laboratory models of MPS I-H.
Important Note
Gene therapy for Hurler syndrome is research only at this stage. It is not an approved treatment. The information below is to explain the science, not to recommend any treatment for individual patients.
Aim of the Preclinical Gene Therapy Study
In simple terms, the programme set out to answer three main questions:
- Can a single, systemic gene therapy dose make cells in the body produce enough alpha-L-iduronidase enzyme?
- Does this reduce the harmful build-up of glycosaminoglycans (GAGs) and improve organ function in MPS I-H models?
- Is the treatment tolerable and biologically safe in the short and medium term, based on preclinical tests?
The studies were performed in established animal models of MPS I-H that lack functional IDUA and develop features similar to the human disease (for example GAG storage, organ enlargement and skeletal and neurological abnormalities).
How the Gene Therapy Vector is Designed
In this programme, researchers used a systemic gene therapy vector designed to:
- Carry a working copy of the human IDUA gene
- Drive expression under a suitable promoter so that transduced cells produce alpha-L-iduronidase
- Be given by intravenous administration (into the bloodstream) so it can reach the liver and other tissues after a single dose
At a high level:
- The vector enters target cells and delivers the IDUA gene to the nucleus.
- The cell's own machinery reads this gene and produces functional alpha-L-iduronidase.
- Some of this enzyme stays within the cell; some is secreted and can be taken up by neighbouring cells through mannose-6-phosphate receptors ("cross-correction").
Enzyme Production
& Cross-Correction
Route of Administration and Dosing in Preclinical Models
In the preclinical experiments:
- The gene therapy was given as a single intravenous infusion to MPS I-H model animals.
- Different dose levels were tested to explore the relationship between vector dose, enzyme production and biological effect.
- Animals were treated at defined ages (for example early in life vs later) to understand how timing affects outcomes, mirroring the importance of early treatment in children with Hurler syndrome.
After dosing, animals were followed for:
- Short-term responses – changes in blood enzyme levels, GAG storage and early safety signals.
- Longer-term effects – organ function, tissue pathology and survival over months, depending on the species and study design.
These studies mirror how a future clinical trial might also need to consider dose, age at treatment and duration of follow up.
Key Endpoints and Readouts
The programme focused on several groups of measures
Biochemical Markers
- Alpha-L-iduronidase activity in blood and relevant tissues
- Levels of dermatan sulfate and heparan sulfate (or related GAG markers) in blood and urine
Tissue and Organ Changes
- Microscopic examination of organs such as liver, spleen, heart, brain and bone for evidence of storage (“vacuolation”)
- Structural imaging or histology to assess skeletal changes where feasible
Functional Outcomes & Safety
- Survival and body weight trajectories
- Basic behavioural or motor assessments in relevant models (for example movement, coordination)
Safety and tolerability
- Clinical observations (behaviour, general health)
- Blood tests (for example liver function, blood counts)
- Evidence of inflammatory reactions or other adverse findings on tissue analysis
Together, these readouts are designed to show whether gene therapy can correct the underlying biochemical defect and whether this translates into meaningful improvements in organ health.
What the Preclinical Study Found
In simple terms, the preclinical programme showed that:
Enzyme Levels Increased
Treated MPS I-H model animals developed measurable alpha-L-iduronidase activity in blood and tissues, whereas untreated animals had little or none. Higher doses tended to give higher sustained enzyme levels.
Storage Markers Fell
Levels of GAGs (or GAG-related biomarkers) in blood and/or urine fell substantially in treated animals compared with untreated disease controls, often moving towards normal ranges observed in healthy animals.
Organs Looked Healthier
Tissue examination showed reduced lysosomal storage in multiple organs (such as liver, spleen, heart and, to varying degrees, other systems) in treated animals compared with untreated animals.
Function and Survival Improved
In many models, treated animals lived longer and had better general condition and growth than untreated animals, supporting a real biological impact rather than just a change in lab tests.
Safety Was Acceptable Within the Study
Within the time frame of these preclinical studies, no major, unexpected safety signals were observed at doses selected for further development. Some dose-related effects and immune responses were noted and are being addressed in ongoing toxicology and design work.
Important context: These findings are encouraging but must be interpreted carefully. Animal models are not identical to human patients, and positive preclinical data do not guarantee success or safety in humans.
Translating Laboratory Findings into Potential Future Treatment
If similar effects could be safely reproduced in humans, systemic gene therapy could:
- Provide long-lasting enzyme production after a single or limited number of doses
- Reduce or remove the need for regular ERT infusions in some settings
- Complement or, in some scenarios, reduce dependence on high-risk procedures such as HSCT
- Improve organ outcomes in tissues that are only partly corrected by current treatment (for example bone, joint and heart valves), though this still needs to be demonstrated
However, important uncertainties remain:
- We do not yet know whether the same levels of enzyme, GAG reduction and organ benefit seen in animals will be achievable and safe in children or adults.
- Gene therapy will still have risks, and long-term monitoring will be essential.
- It is not yet clear how gene therapy would fit with, or replace, HSCT and ERT in different real-world situations.
This is why careful clinical trials are needed, built on the preclinical data.
What the Studies Cannot Tell Us Yet
Important limitations include:
- Species differences: The way gene therapy vectors behave, and how disease presents, can differ between animals and humans.
- Follow up length: Preclinical studies can only follow animals for a limited time. Human patients with Hurler syndrome live for many years after treatment, so long-term safety and durability in people remain unknown.
- Doses and scale: Doses are scaled when moving from animals to humans, and manufacturing constraints may affect what is feasible clinically.
- Disease stage at treatment: Most preclinical models are treated relatively early. Outcomes in older children or adults with established damage may be different.
These limitations are typical of early gene therapy research and are the reason that further toxicology work, regulatory review and carefully designed clinical trials are required before routine clinical use.
From Preclinical Programme to Human Trials
The logical next stages, informed by the preclinical results, include:
- Formal toxicology studies in relevant species under regulatory standards, at and above the intended clinical dose range
- Refinement of vector design or dosing if needed to balance efficacy and safety
- Manufacturing development to produce clinical-grade vector at consistent quality
- Regulatory engagement (for example with medicines agencies) to agree on a first-in-human trial design
- Design of early-phase clinical trials, typically starting with a small number of carefully selected patients, with intensive monitoring and long-term follow up
Families and clinicians will be informed about any future trial opportunities through specialist centres, registries and recognised patient organisations.
Important Information for Different Audiences
For Clinicians and Researchers
How to Use This Summary
- Explain, in plain language, the logic and early evidence behind systemic gene therapy to families and colleagues
- Place future clinical trial proposals in context, alongside current standard of care (HSCT +/- ERT) and unmet needs
- Identify key domains for outcome measures (enzyme activity, GAG levels, organ pathology, function, safety) when designing or reviewing studies
- Encourage a balanced discussion of promise and uncertainty, avoiding both unrealistic optimism and undue pessimis
For Families
Key Takeaway Messages
- This gene therapy work has been done in the laboratory and in animal models, not yet as routine treatment in people with Hurler syndrome.
- Results so far suggest that a single systemic dose can increase enzyme levels, reduce storage markers and improve organ health in these models.
- Gene therapy offers hope as a future option, especially to reduce long-term treatment burden and address remaining unmet needs, but it is not available as a standard treatment now.
- Decisions about joining any future gene therapy trial should always be made with your specialist team, with full information about potential benefits, risks and unknowns.
Key Points About the Preclinical Gene Therapy Programme
- A systemic gene therapy vector delivering a functional IDUA gene has been tested in established MPS I-H animal models.
- A single intravenous dose led to increased alpha-L-iduronidase activity, reduction in GAG storage markers, and improved organ pathology and survival in these models.
- Short- to medium-term safety was acceptable within the scope of the preclinical studies, but long-term human safety and durability are still unknown.
- These results support further development towards toxicology studies and, if appropriate, early-phase clinical trials, but do not yet justify routine use in patients.
- Families and professionals should view these findings as an important step in research, not as a guaranteed future treatment.
What to read next
Research hub
Main research themes and programmes
Rationale for Gene Therapy
Why systemic gene therapy is being explored in MPS I-H
Scientific background
Molecular and cellular mechanisms of Hurler syndrome
Unmet need
Residual morbidity after HSCT and ERT
Current standard of care
HSCT, ERT and multidisciplinary management
Clinical trials and research
How to interpret and consider participation in studies